Patent · US Active

Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors

US11993614B2 · kind B2 · utility

0Cited by

5References

16Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Tongfei Wu · Leuven, BE
Dirk Brehmer · Glückstadt, DE
Lijs Beke · Ekeren, BE
An Boeckx · Herentals, BE
Gaston Stanislas Marcella Diels · Turnhout, BE
Edward C. Lawson · Pipersville, US
Lieven Meerpoel · Beerse, BE
Vineet Pande · Vosselaar, BE
Marcus Cornelius Bernardus Catharina Parade · Eindhoven, NL
Wim Bert Griet Schepens · Sint-Katelijne-Waver, BE
Weimei Sun · North Wales, US
Johannes Wilhelmus John F. Thuring · Ekeren, BE
Marcel Viellevoye · Breda, NL

Key dates

Filing date	Jul 16, 2021
Grant date	May 28, 2024
Priority date	—
Expiry date	Jul 16, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I), wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.